Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pathway ahead in melanoma trials.

Oncology (Williston Park, N.Y.) - 1 May 2009

Miller Arlo J, Markovic Svetomir N, Haluska Paul

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Clinical Trials as Topic
Share to Cyclin-Dependent Kinase 4
Share to Cyclin-Dependent Kinase Inhibitor p16

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, p16

Share to Neovascularization, Pathologic

Share to ras Proteins

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 19544690

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pathway ahead in melanoma trials.PMID 19544690Read ↗

Melanoma's next top model, it is in the air.Semantic proximity Read ↗

Development of Personalized Strategies for Precisely Battling Malignant Melanoma.Semantic proximity Read ↗

[Guidelines for stage I to III melanoma].Semantic proximity Read ↗

Melanoma as a model for precision medicine in oncology.Semantic proximity Read ↗

[Paradigmatic shift in oncology: individualized melanoma treatment].Semantic proximity Read ↗

Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress.Semantic proximity Read ↗

Messing with cancer therapy: how the melanoma phenotype predicts checkpoint inhibitor response.Semantic proximity Read ↗

Evolution of Molecular Targets in Melanoma Treatment.Semantic proximity Read ↗

Molecular therapy for melanoma: useful and not useful targets.Semantic proximity Read ↗

Beyond BRAF: where next for melanoma therapy?Semantic proximity Read ↗

Advances in drug development. BRAF validation in melanoma.Semantic proximity Read ↗

Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.